Cipher PharmaceuticalsCPHRF 96 Return-on-Tangible-Equity is 60.69% as of Mar. 2026, which is 34% above its 10-year median of 45.38. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.20 (Fairly Valued). The stock has 5 warning signs investors should review. Among 897 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 92.87% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cipher Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was $24.65 Mil. Cipher Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $40.62 Mil. Therefore, Cipher Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 60.69%.
The historical rank and industry rank for Cipher Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
CPHRF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2602.59 Med: 45.38 Max: 126.74
Current: 116.94
During the past 13 years, Cipher Pharmaceuticals's highest Return-on-Tangible-Equity was 126.74%. The lowest was -2,602.59%. And the median was 45.38%.
CPHRF's Return-on-Tangible-Equity is ranked better than 92.87% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs CPHRF: 116.94
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cipher Pharmaceuticals Return-on-Tangible-Equity Related Terms
Cipher Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cipher Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPHRF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipher Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cipher Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 60.69% mean?
Cipher Pharmaceuticals (CPHRF) has a Return-on-Tangible-Equity of 60.69% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cipher Pharmaceuticals and its competitors. This is 34% above median its historical median of 45.38. According to the industry distribution chart, Cipher Pharmaceuticals ranks #64 out of 897 companies in the Drug Manufacturers industry, placing it in the top 7.1%.
Is Cipher Pharmaceuticals' Return-on-Tangible-Equity too high?
Cipher Pharmaceuticals' current Return-on-Tangible-Equity of 60.69% is 34% above median its 10-year median of 45.38. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Cipher Pharmaceuticals' value of 60.69% is 668.2% above this industry median. Based on the distribution chart, Cipher Pharmaceuticals ranks #64 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #64 out of 897 companies for Return-on-Tangible-Equity. This places Cipher Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Cipher Pharmaceuticals' value of 60.69% is 668.2% above this benchmark. While the company's 10-year median is 45.38 vs. the industry median of 7.90, Cipher Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipher Pharmaceuticals's current Return-on-Tangible-Equity of 60.69% is 668.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cipher Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipher Pharmaceuticals's current Return-on-Tangible-Equity is 60.69%, which is 34% above median its own 10-year median of 45.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.20, compared to a current price of $11.77 — trading 3.6% below its estimated fair value. The current Return-on-Tangible-Equity is 60.69%, which is 34% above median its 10-year median of 45.38 and 668.2% above the Drug Manufacturers industry median of 7.90. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current Return-on-Tangible-Equity is 60.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?
Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.77 is trading 3.6% below its estimated GF Value™ of $12.20.
GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.
Key valuation signals for CPHRF:
Return-on-Tangible-Equity: 60.69% (34% above median its 10-year median of 45.38)
GF Value™: $12.20 vs. price of $11.77 (3.6% below fair value)
Industry Position: 668.2% above the Drug Manufacturers median (#64 of 897)
No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score
Get the complete analysis for CPHRF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHRF has been successfully added to your 
